Class information for:
Level 1: 5T4//TUMOR IMMUNOL BIOL//5T4 ONCOFETAL ANTIGEN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
16110 605 47.5 89%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
151 22214 IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 5T4 Author keyword 32 88% 2% 15
2 TUMOR IMMUNOL BIOL Address 31 25% 18% 110
3 5T4 ONCOFETAL ANTIGEN Author keyword 23 100% 2% 10
4 TRICOM Author keyword 8 70% 1% 7
5 TROVAX Author keyword 7 67% 1% 6
6 JR GRP VIROL IMMUNOL Address 6 80% 1% 4
7 MEDAWAR Address 5 24% 3% 20
8 5T4 TUMOR ANTIGEN Author keyword 4 75% 0% 3
9 MUTANT P21 RAS Author keyword 4 75% 0% 3
10 RAS PEPTIDES Author keyword 4 75% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 5T4 32 88% 2% 15 Search 5T4 Search 5T4
2 5T4 ONCOFETAL ANTIGEN 23 100% 2% 10 Search 5T4+ONCOFETAL+ANTIGEN Search 5T4+ONCOFETAL+ANTIGEN
3 TRICOM 8 70% 1% 7 Search TRICOM Search TRICOM
4 TROVAX 7 67% 1% 6 Search TROVAX Search TROVAX
5 5T4 TUMOR ANTIGEN 4 75% 0% 3 Search 5T4+TUMOR+ANTIGEN Search 5T4+TUMOR+ANTIGEN
6 MUTANT P21 RAS 4 75% 0% 3 Search MUTANT+P21+RAS Search MUTANT+P21+RAS
7 RAS PEPTIDES 4 75% 0% 3 Search RAS+PEPTIDES Search RAS+PEPTIDES
8 5T4 ONCOFOETAL ANTIGEN 3 100% 0% 3 Search 5T4+ONCOFOETAL+ANTIGEN Search 5T4+ONCOFOETAL+ANTIGEN
9 P53 PEPTIDES 3 100% 0% 3 Search P53+PEPTIDES Search P53+PEPTIDES
10 RAS DERIVED PEPTIDES 3 100% 0% 3 Search RAS+DERIVED+PEPTIDES Search RAS+DERIVED+PEPTIDES

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TROPHOBLAST GLYCOPROTEIN 34 93% 2% 13
2 HUMAN CARCINOEMBRYONIC ANTIGEN 33 33% 14% 82
3 DIVERSIFIED PRIME 20 58% 4% 23
4 TARGETING P53 18 89% 1% 8
5 ANTIGEN 5T4 TROVAX 14 55% 3% 17
6 POTENT IMMUNE RESPONSES 14 55% 3% 17
7 TROVAX 12 86% 1% 6
8 ONCOFETAL ANTIGEN 11 36% 4% 24
9 OVERLAPPING EPITOPES 11 78% 1% 7
10 CEA TRANSGENIC MICE 9 50% 2% 13

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Carcinoembryonic antigen-based vaccines 2003 41 10 90%
Viral Vector-Based Therapeutic Cancer Vaccines 2011 24 83 39%
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines 2012 22 57 39%
Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise 2013 6 78 44%
TRICOM vector based cancer vaccines 2006 28 38 53%
Therapeutic Cancer Vaccines: Current Status and Moving Forward 2012 86 191 10%
Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials 2012 9 172 42%
Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review 2002 85 64 27%
Vaccines based on whole recombinant Saccharomyces cerevisiae cells 2010 19 40 33%
Poxviral vectors for cancer immunotherapy 2012 11 89 34%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TUMOR IMMUNOL BIOL 31 25% 18% 110
2 JR GRP VIROL IMMUNOL 6 80% 0.7% 4
3 MEDAWAR 5 24% 3.3% 20
4 CANC UK IMMUNOL GRP 3 42% 0.8% 5
5 SECT PHARMACOL MED ONCOL 3 42% 0.8% 5
6 CRUK IMMUNOL GRP 2 67% 0.3% 2
7 CR UK IMMUNOL GRP 2 50% 0.5% 3
8 CRC IMMUNOL GRP 1 100% 0.3% 2
9 SECT IMMUNOTHER Y 1 14% 1.0% 6
10 CANC VACCINE BRANCH 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000220256 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
2 0.0000180064 BELAGENPUMATUCEL L//SRL172//PA MSHA
3 0.0000180063 CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1
4 0.0000172402 RECOMBINANT VACCINE GRP//ABSCOPAL EFFECT//IMMUNOGENIC TUMOR CELL DEATH
5 0.0000130779 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
6 0.0000112637 CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION
7 0.0000108405 CEACAM1//BILIARY GLYCOPROTEIN//CD66A
8 0.0000106431 DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE
9 0.0000094654 FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL
10 0.0000089870 ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE